Monash Children’s Cancer Biobank and Living Biobank
About the Monash Children’s Cancer Biobank
The Monash Children’s Cancer Biobank is collaboratively operated at the Centre for Cancer Research at Hudson Institute, and by Monash Children’s Cancer Centre. Established in 2011, the biobank provides an unparalleled research platform for investigators focused on childhood, adolescent, and young adult cancers. Since its inception, the biobank has accumulated a rich collection of biospecimens that reflect the diverse types of paediatric cancer. These samples include solid tumour tissue, skin, blood, and bone marrow, all of which are linked to comprehensive biological and health information.
Supporting clinical trials and research
Samples from the Monash Children’s Cancer Biobank are instrumental in
supporting clinical trial applications, novel clinical molecular testing, therapy development, and a wide range of national and international translational research projects. This biobank plays a crucial role in delivering advanced genomic testing and developing precision treatments for
children with cancer.
Living Biobank for paediatric brain cancers
Powered by the Lindonlight Collective, the living biobank for paediatric brain cancers is developing avatar models for the most lethal children’s brain cancers, including DIPG, medulloblastoma, gliomas, ATRT, ETMR and ependymomas. We’re developing models such as cell lines, patient-derived xenografts (PDXs) and three-dimensional organoid models which serve as research tools to develop precision therapies.
Living Biobank for childhood and adolescent solid tumours
The Childhood and Adolescent solid tumour Living Biobank is focused on the development of novel models of extracranial cancers, including sarcomas and other rare tumours. Patient-derived xenograft model development is leveraged for additional cell culture model establishment. Coupled with molecular characterisation, this offers complementary patient-derived models, providing a vital resource for innovative research into childhood cancer.
Future impact
The Monash Children’s Cancer Biobank directly benefits a unique patient cohort of children with limited treatment options and poor prognoses, who often endure severe long-term side effects from treatment. By providing access to tumour tissue and matched clinical data, the biobank enables researchers to improve treatment options, enhance years of life saved, and significantly enhance the quality of life for children with cancer.
Contact
For more information or enquiries about the MCH Biobank: Dilru.Habarakada@hudson.org.au
For more information or enquiries about the Living Biobank for paediatric brain cancers: ron.firestein@hudson.org.au
For more information or enquiries about the Living Biobank for extracranial tumours: jason.cain@hudson.org.au